Summary MAC 16 is one of a series of mouse colon tumours originally induced by dimethylhydrazine. It is a relatively slow growing subcutaneous adenocarcinoma which becomes necrotic as it grows and causes severe body wasting in the host. This study has indicated that the tumour is resistant to a large number of standard anti-cancer drugs but is highly responsive to the investigational agent flavone acetic acid (FAA). The levels of FAA achieved in tumours are lower than those necessary for activity in vitro suggesting its mechanism of action in vivo is not (Corbett et al., 1986; Plowman et al., 1986; Bibby et al., 1987a concentrations for a desired dose to be administered in 0.1 ml per lOg body weight. Drugs were made up immediately before use and all injections were i.p.
Flavone acetic acid (FAA) is a novel anti-tumour agent under early clinical investigation in Europe and the USA. The rationale for the submission of this compound for clinical trial was significant anti-tumour effects in solid murine tumours (Corbett et al., 1986; Plowman et al., 1986; Bibby et al., 1987a) . Initial clinical investigations have demonstrated that FAA is also devoid of bone marrow toxicity (Kerr et al., 1986) . MAC 16 is one of a panel of mouse adenocarcinomas of the colon initially induced by 1,2-dimethylhydrazine (Haase et al., 1973) . The tumour system has been extensively used in experimental chemotherapy studies but the chemosensitivity of MAC 16 has not been fully evaluated. Preliminary chemosensitivity studies with MAC 16 (Ali et al., 1985) demonstrated that the tumour was moderately responsive to 5-fluorouracil (5FU) and cyclophosphamide but did not respond to methyl-CCNU (MeCCNU) or mitozolomide. Implantation of MAC 16 results in a significant loss of host body weight without excessive tumour mass and without a concomitant reduction of food intake by the host (Bibby et al., 1987b) . The present study examines the anti-tumour effects of FAA and a series of standard anti-cancer agents on MAC 16 and also investigates plasma and tumour levels of FAA.
Materials and methods

Animals
Pure strain NMRI mice (age 6-8 weeks) from our inbred colony were used. They were fed on CRM Diet (Labsure, UK) and water ad libitum. concentrations for a desired dose to be administered in 0.1 ml per lOg body weight. Drugs were made up immediately before use and all injections were i.p.
Tumours
The development of several transplantable adenocarcinomas of the large bowel in mice from primary tumours induced by prolonged administration of 1,2,dimethylhydrazine has been described elsewhere (Double et al., 1975) . MAC 16 tumours were excised from donor animals and placed in sterile 0.9% saline containing streptomycin (2mg ml -') and penicillin (2000 U ml-1) and cut into small fragments 1 x 2mm in size. Fragments were implanted s.c. into the flank by means of a trocar. Take rates are variable with good rates being dependent on careful implantation of viable tumour fragments. Positive takes can only be identified 2-3 weeks after implantation.
Chemotherapy
Tumour bearing animals were allocated by restricted randomisation into groups of 10. Chemotherapy did not commence until the tumours could be reliably measured, i.e. until they achieved minimum dimensions of 4 x 5 mm. Therapeutic effects were assessed by twice weekly 2-dimensional caliper measurements of the tumour. Tumour volume was calculated from the formula a2 x b/2 where a is the smaller diameter and b is the larger (Geran et al., 1972 (1985) . Tumour samples were mixed with 0.1 M sodium acetate-acetic acid buffer, pH4 (10% w/v) and homogenised using an Ultraturrax blender. Homogenates were centrifuged at 2500g and 4°C for 5 min. The supernatants were separated and after the addition of internal standard, p-dimethylaminobenzaldehyde (100 ,ul at 100 ug ml -') were extracted for analysis. Standard curves were prepared by the addition of FAA to buffered control mouse plasma (pH4) and plotting ratio of peak areas of FAA to the internal standard against drug concentration. Figure 1 . A dose of 300mg kg-1 is acutely toxic with 4 out of 10 deaths occurring in this group. Treatment with 200mg kg-1 on 0 and day 7 results in a highly significant growth delay with 8 out of 10 mice in this group being cured and no drug associated deaths. ThioTEPA at the LD1O produces a very short cessation of tumour growth but tumour growth rapidly returns to control level.
Growth of MAC 16 in untreated animals is accompanied by a dramatic body weight loss (Figure 2 ). Treatment with FAA causes a rapid recovery in body weight. The interim anti-tumour effect caused by ThioTEPA at the LDIO is also accompanied by a cessation of body weight loss, but the rapid regrowth of the tumour is accompanied by a drop in body weight until this group reaches the same mean body weight as the untreated control group.
The histology of MAC 16 tumours which respond to FAA but are not cured is shown in Figure 3 . The normal histology of the appropriate passage is shown in Figure 3a and the effects of FAA on tumours of that passage are shown in Figures 3b and 3c . The viable tumour cells are associated with vessels within the tumour whereas the vast (Bibby et al. 1987b ) and this appears to have influenced responses and drug tolerance. There are no major histological differences between early and late tumour passages and the degree of necrosis of the tumour relates to tumour size. The histology, growth characteristics and resistance of this tumour suggests it may be a clinically relevant model for the evaluation of potential anti-cancer drugs. The i.p. maximum tolerated dose (MTD) of FAA in female NMRI mice bearing MAC 16 tumours was 200mgkg-1 whereas the MTD in non-tumour bearing mice and those bearing other tumours of the MAC system was 300mgkg-1 (Bibby et al. 1987a) . Previous experimental chemotherapy studies have shown that FAA is most active against other subcutaneous MAC tumours when administered by a two dose schedule split by seven days (Bibby et al. 1987a of Corbett et al. (1986) that for the first time an agent has been identified with a very broad, perhaps nearly universal solid tumour activity.
The pharmacokinetic data in this study following a dose of 200mgkg-1 FAA suggests that the anti-tumour effects are not the result of a direct cytotoxic mechanism. Previous in vitro studies with a variety of tumour cell lines indicate that high drug concentrations and long exposure times are necessary to achieve direct cytotoxicity (Bibby et al., 1987a; Capolonga et al., 1987; Schroyens et al., 1987 Smith et al. (1987) have described the induction of haemorrhagic necrosis in mouse colon 26 and colon 38 tumours and suggest that FAA may work in a similar fashion to tumour necrosis factor (TNF). Ching and Baguley (1987) and Wiltrout (1987) have also suggested that natural killer (NK) cells may be involved in the mechanisms of action of FAA as it activates NK cell activity in mice.
In preliminary studies in this laboratory with another tumour line (Bibby et al,. 1987c) (1987) have suggested that anti-tumour effects in mice may be related to altered platelet function following FAA treatment.
In conclusion FAA is highly active in a mouse colon tumour which is resistant to a number of standard anticancer drugs. The tolerance of MAC 16 tumour bearers to standard agents and FAA is impaired but responses are still achieved with FAA. The anti-tumour effects are accompanied by control of the tumour associated cachexia. The low tumour concentrations and the unique chemosensitivity suggest that FAA is working by a completely novel mechanism for a chemotherapeutic agent. The plasma profiles associated with activity against subcutaneous tumours in mice have now been attained in man (Kerr et al., 1987) 
